Table 1.
Clinical data of the pleural mesothelioma (PM) cohort.
| Cases | |||
|---|---|---|---|
| All Patients | Long Survival | Short Survival | |
| n (%) | n (%) | n (%) | |
| Cohort | 129 | 45 | 54 |
| Median age (years), range | 77 (34–97) | 73 (52–91) | 82 (34–97) |
| Gender (%) | |||
| Male | 97 (75.2) | 36 (80.0) | 34 (63.0) |
| Female | 32 (24.8) | 9 (20.0) | 20 (37.0) |
| Histologic subtype | |||
| Epithelioid (ePM) | 99 (77) | 45 (100.0) | 54 (100.0) |
| Non-epithelioid (non-ePM) | 30 (23) | 0 (0.0) | 0 (0.0) |
| Survival classification 1 | |||
| Long survival (>36 months) | 45 (34.9) | 45 (100.0) | 0 (0.0) |
| Short survival (<12 months) | 54 (41.9) | 0 (0.0) | 54 (100.0) |
| Other | 30 (23.3) | 0 (0.0) | 0 (0.0) |
| ECOG performance status | |||
| 0 | 49 (38.0) | 24 (53.3) | 16 (29.6) |
| 1 | 12 (9.3) | 6 (13.3) | 4 (7.4) |
| 2 | 5 (3.9) | 0 (0.0) | 2 (3.7) |
| 3 | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Unknown | 62 (48.1) | 15 (33.3) | 32 (59.3) |
| First line treatment | |||
| No | 22 (17.1) | 0 | 10 (18.5) |
| Carboplatin + pemetrexed | 22 (17.1) | 7 (15.6) | 8 (14.8) |
| Cisplatin + pemetrexed | 6 (4.7) | 5 (11.1) | 1 (1.9) |
| Platin derivate + pemetrexed + Additional drug | 4 (3.1) | 1 (2.2) | 3 (5.6) |
| Treatment combination not containing platinum + pemetrexed | 5 (3.9) | 1 (2.2) | 2 (3.7) |
| Unknown | 70 (54.3) | 31 (68.9) | 30 (55.6) |
| Surgery | |||
| Yes | 19 (14.7) | 18 (40.0) | 1 (1.9) |
| No | 109 (84.5) | 26 (57.8) | 53 (98.2) |
| Unknown | 1 (0.8) | 1 (2.2) | 0 (0.0) |
| Radiotherapy | |||
| Yes | 10 (7.8) | 10 (22.2) | 0 (0.0) |
| No | 117 (90.7) | 33 (73.3) | 54 (100.0) |
| Unknown | 2 (1.6) | 2 (4.4) | 0 (0.0) |
1 Only for ePM subtype.